Table 2.

Combinations of therapeutic targets (from the TTD database) that perturb the RA macrophages’ phenotypes.

Synergistic combination in the model	Targets	Target type	Associated disease(s)	Drugs with highest status	Effect of the RA macrophages' phenotypes
JAK1 and JAK2	JAK1	Successful targets	Acquired hypomelanotic disorder, Atopic eczema, Crohn disease, Myeloproliferative neoplasm, Pancreatic cancer, ...	Baricitinib (Approved)	-Induction of the M1 macrophage apoptosis -Suppression of the M1 macrophage proliferation
	JAK2	Successful targets	Acquired hypomelanotic disorder, Atopic eczema, Myeloproliferative neoplasm, Pancreatic cancer, Rheumatoid arthritis, ...	Baricitinib (Approved)
ERK1 and Notch1	ERK1	Clinical trial target	Melanoma, Pancreatic cancer, Cancer, Arteries/arterioles disorder, Mature T-cell lymphoma.	BVD-523 (Phase 2)	-Induction of the M1 macrophage apoptosis -Suppression of the M1 macrophage proliferation
	Notch1	Clinical trial target	Lymphoma, Mature T-cell lymphoma, Cancer.	LY3039478 (Phase 1/2)